204 related articles for article (PubMed ID: 30392335)
1. [Research progression of prophylactic HPV vaccine application].
Zhang L; Zhao FH
Zhonghua Zhong Liu Za Zhi; 2018 Oct; 40(10):724-728. PubMed ID: 30392335
[TBL] [Abstract][Full Text] [Related]
2. Spotlight on quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine(Gardasil®) in the prevention of premalignant genital lesions, genital cancer, and genital warts in women.
McCormack PL; Joura EA
BioDrugs; 2011 Oct; 25(5):339-43. PubMed ID: 21942919
[TBL] [Abstract][Full Text] [Related]
3. The Australian experience with the human papillomavirus vaccine.
Garland SM
Clin Ther; 2014 Jan; 36(1):17-23. PubMed ID: 24417782
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of HPV vaccines against genital warts in women from Valencia, Spain.
Navarro-Illana E; López-Lacort M; Navarro-Illana P; Vilata JJ; Diez-Domingo J
Vaccine; 2017 Jun; 35(25):3342-3346. PubMed ID: 28499554
[TBL] [Abstract][Full Text] [Related]
5. Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis.
Drolet M; Bénard É; Boily MC; Ali H; Baandrup L; Bauer H; Beddows S; Brisson J; Brotherton JM; Cummings T; Donovan B; Fairley CK; Flagg EW; Johnson AM; Kahn JA; Kavanagh K; Kjaer SK; Kliewer EV; Lemieux-Mellouki P; Markowitz L; Mboup A; Mesher D; Niccolai L; Oliphant J; Pollock KG; Soldan K; Sonnenberg P; Tabrizi SN; Tanton C; Brisson M
Lancet Infect Dis; 2015 May; 15(5):565-80. PubMed ID: 25744474
[TBL] [Abstract][Full Text] [Related]
6. Impact of HPV immunization on the detection of cervical disease.
Munro AJ; Cruickshank ME
Expert Rev Vaccines; 2014 Apr; 13(4):533-44. PubMed ID: 24606579
[TBL] [Abstract][Full Text] [Related]
7. Gender-neutrality, herd effect and resilient immune response for sustainable impact of HPV vaccination.
Lehtinen M; Apter D
Curr Opin Obstet Gynecol; 2015 Oct; 27(5):326-32. PubMed ID: 26308204
[TBL] [Abstract][Full Text] [Related]
8. Human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for the prevention of cervical cancer and HPV-related diseases.
Skinner SR; Apter D; De Carvalho N; Harper DM; Konno R; Paavonen J; Romanowski B; Roteli-Martins C; Burlet N; Mihalyi A; Struyf F
Expert Rev Vaccines; 2016; 15(3):367-87. PubMed ID: 26902666
[TBL] [Abstract][Full Text] [Related]
9. HPV vaccines to prevent cervical cancer and genital warts: an update.
Dochez C; Bogers JJ; Verhelst R; Rees H
Vaccine; 2014 Mar; 32(14):1595-601. PubMed ID: 24606637
[TBL] [Abstract][Full Text] [Related]
10. Impact and Effectiveness of the Quadrivalent Human Papillomavirus Vaccine: A Systematic Review of 10 Years of Real-world Experience.
Garland SM; Kjaer SK; Muñoz N; Block SL; Brown DR; DiNubile MJ; Lindsay BR; Kuter BJ; Perez G; Dominiak-Felden G; Saah AJ; Drury R; Das R; Velicer C
Clin Infect Dis; 2016 Aug; 63(4):519-27. PubMed ID: 27230391
[TBL] [Abstract][Full Text] [Related]
11. Knowledge of sexually transmitted HPV infection, genitoanal warts, cancer and their prevention among young females after vaccine introduction in Germany.
Kuznetsov AV; Müller RA; Ruzicka T; Herzinger T; Kuznetsov L
J Eur Acad Dermatol Venereol; 2013 Dec; 27(12):1527-34. PubMed ID: 23216713
[TBL] [Abstract][Full Text] [Related]
12. Progress in prophylactic human papillomavirus (HPV) vaccination in 2016: A literature review.
Maver PJ; Poljak M
Vaccine; 2018 Aug; 36(36):5416-5423. PubMed ID: 28801154
[TBL] [Abstract][Full Text] [Related]
13. Updates on human papillomavirus and genital warts and counseling messages from the 2010 Sexually Transmitted Diseases Treatment Guidelines.
Dunne EF; Friedman A; Datta SD; Markowitz LE; Workowski KA
Clin Infect Dis; 2011 Dec; 53 Suppl 3():S143-52. PubMed ID: 22080267
[TBL] [Abstract][Full Text] [Related]
14. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up.
Villa LL; Costa RL; Petta CA; Andrade RP; Paavonen J; Iversen OE; Olsson SE; Høye J; Steinwall M; Riis-Johannessen G; Andersson-Ellstrom A; Elfgren K; Krogh Gv; Lehtinen M; Malm C; Tamms GM; Giacoletti K; Lupinacci L; Railkar R; Taddeo FJ; Bryan J; Esser MT; Sings HL; Saah AJ; Barr E
Br J Cancer; 2006 Dec; 95(11):1459-66. PubMed ID: 17117182
[TBL] [Abstract][Full Text] [Related]
15. 9-Valent HPV vaccine for cancers, pre-cancers and genital warts related to HPV.
Pitisuttithum P; Velicer C; Luxembourg A
Expert Rev Vaccines; 2015; 14(11):1405-19. PubMed ID: 26366475
[TBL] [Abstract][Full Text] [Related]
16. Human papillomavirus vaccines and vaccine implementation.
de Sanjosé S; Alemany L; Castellsagué X; Bosch FX
Womens Health (Lond); 2008 Nov; 4(6):595-604. PubMed ID: 19072462
[TBL] [Abstract][Full Text] [Related]
17. [AN HPV-ASSOCIATED DISEASES AND CERVICAL CANCER AND PROPHYLACTIC HUMAN PAPILLOMAVIRUS (HPV) VACCINES].
Malinova M
Akush Ginekol (Sofiia); 2015; 54 Suppl 1():25-31. PubMed ID: 26137767
[TBL] [Abstract][Full Text] [Related]
18. 9-Valent human papillomavirus vaccine: a review of the clinical development program.
Luxembourg A; Moeller E
Expert Rev Vaccines; 2017 Nov; 16(11):1119-1139. PubMed ID: 28956458
[TBL] [Abstract][Full Text] [Related]
19. From the monovalent to the nine-valent HPV vaccine.
Pils S; Joura EA
Clin Microbiol Infect; 2015 Sep; 21(9):827-33. PubMed ID: 25980355
[TBL] [Abstract][Full Text] [Related]
20. A prophylactic quadrivalent vaccine for the prevention of infection and disease related to HPV-6, -11, -16 and -18.
Goldstone SE; Vuocolo S
Expert Rev Vaccines; 2012 Apr; 11(4):395-406. PubMed ID: 22551023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]